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Background: Patients with many types of autoimmune diseases (AIDs) are at an increased risk of cancer, which may
depend on underlying dysregulation of the immune system or treatment. We systematically analyzed myeloma risk
and survival in patients diagnosed with 33 different AIDs.
Methods: Data on patients with AIDs were retrieved from the Swedish Hospital Discharge Register and were linked
to myeloma diagnoses from the Cancer Registry. Standardized incidence ratios (SIR) and hazard ratios (HRs) were
calculated for subsequent myeloma between 1964 and 2008.
Results: Among patients with the 33 AIDs analyzed, 457 cases of myeloma were diagnosed. The overall SIR for
myeloma was 1.12 and the overall HR was 0.92 and non-significant. SIRs for myeloma were significantly increased
after ankylosing spondylitis (2.02) and systemic sclerosis (2.63). Only the HR for myeloma after rheumatic fever (5.27)
was significantly increased. The SIR for myeloma before age 60 years was 1.45; the SIR for myeloma was only
increased in the period 1964–1990 (1.31) and not later (1.04). Only the SIR for myeloma after ankylosing spondylitis
was increased in the period 1991–2008 (2.09); the HRs for myeloma were increased after polymyositis/
dermatomyositis (6.44) and rheumatic fever (4.43) but there were only three deaths of myeloma after these AIDs.
Conclusions: The present data showed an increase in myeloma SIR after two AIDs, ankylosing spondylitis and
systemic sclerosis, and in HR after rheumatic fever. The overall myeloma risk after any AID was no longer increased in
the latter follow-up period of 1991 through 2008.
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Autoimmune (AI) diseases (AIDs) constitute many dif-
ferent diseases with systemic or local manifestations,
which jointly affect 5 to 10% of the population in the
developed countries [1]. AIDs are characterized by the
activation of T cells or B cells, or both, in the absence of
an ongoing infection. The normal function of these cells
is to recognize specific foreign antigens, but they possess
a low level of autoreactivity towards own (self or auto)
antigens. In AIDs, autoreactivity is increased and symp-
toms develop [2]. Many cancers are increased in AID
patients for reasons that are not known [3-6]. The im-
munological disturbances in AIDs may be an important* Correspondence: k.hemminki@dkfz.de
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distribution, and reproduction in any mediummechanism to cancer formation because cancers typically
arise in organs with AI manifestations [3-6]. However,
treatment with immunosuppressive therapy may also
contribute [7]. Many AIDs are treated with nonsteroidal
anti-inflammatory drugs and as these are protective
against many cancers, they may help to hide carcinogenic
effects of AIDs [8].
Multiple myeloma is an incurable malignant disease of
clonal plasma cells, which accumulate in the bone mar-
row and cause clinical sequelae characterized by the pro-
duction of monoclonal protein, displacement of normal
hematopoiesis, bone marrow neovascularization, forma-
tion of osteolytic bone lesions, hypercalcemia and renal
failure [9]. Myeloma arises from B-cells with somatic
hypermutations in the variable region immunoglobin
genes [10]. Hypermutations occur in germinal centers
and thus myeloma development is thought to be related
to post-germinal center immune stimulation. Chronic
antigenic stimulation has long been suggested to drivetral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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history of rheumatic fever and urinary tract infections
was associated with myeloma risk [12]. Myeloma risks
have also been associated with pernicious anemia and
polymyalgia rheumatic in previous Swedish studies
[3,13]. In US veterans, myeloma risk was associated with
polymyositis/dermatomyositis, systemic sclerosis, auto-
immune hemolytic anemia, pernicious anemia and anky-
losing spondylitis [4]. The data on rheumatoid arthritis
has been controversial and data on Crohn disease and
sarcoidosis have been negative [3,14,15]. Whether AID
influences myeloma survival has deserved less attention
and the studies on survival after rheumatoid arthritis,
Crohn disease, ulcerative colitis and psoriasis have shown
no effect [16-18].
In the present study we examined risks of myeloma
(standardized incidence ratio, SIR) and survival in mye-
loma (hazard ratio, HR) systematically in patients, who
had been hospitalized for any of 33 AIDs, covering the
total Swedish population. As myeloma treatment has
changed over the years with improvements in survival,
we analyzed also periodic effects [19].
Material and methods
The research dataset used in the present study is a subset
of the national dataset maintained at the Center for
Primary Health Care Research, Lund University, Malmö,
Sweden, and has been used previously [6]. AID patients
were identified from the Swedish Hospital Discharge
Register, which contains data on all hospital discharges
(dates of hospitalization and diagnoses) for some regions
of Sweden since 1964 and for the whole of Sweden since
1986. The International Classification of Diseases codes
used have been described previously [20,21]. A total of
33 AIDS were covered. However, for 12 AIDs (Addison’s
disease, amyotrophic lateral sclerosis, autoimmune
hemolytic anemia, celiac disease, chorea minor, type 1
diabetes, discoid lupus, localized scleroderma, lupoid
hepatitis, polyarteritis nodosa, primary biliary cirrhosis
and Reiter’s disease) there were fewer than four cases of
myeloma. These diseases were not significantly asso-
ciated with myeloma (as assessed by SIR and HR) and
data are not shown for them. The linkages were per-
formed by means of the individual national identification
number that is assigned to each person in Sweden for
their lifetime. This number was replaced by a serial num-
ber for each person in order to provide anonymity.
SIRs were calculated as the ratio of observed to
expected number of myelomas. Expected numbers were
calculated for anyone not hospitalized for AID. The
expected numbers were calculated as age (5-year groups),
sex, period (5-year groups), region and socioeconomic
status-specific standard incidence rates. Additional adjust-
ments were made for hospitalization for obesity usingcodes ICD7 = 287.00, 287.09; ICD8 = 277.99; ICD9 =
278A; ICD-10= E65-E68. A total of 30,020 individuals
had been hospitalized for obesity. Similar adjustments
were made for smoking using hospitalization for chronic
obstructive pulmonary disease as a surrogate with 260,243
individuals affected (codes: ICD7 = 500–502; ICD8 =
490–493; ICD9 =490-496; ICD-10= J40-J49), and alcohol
using alcoholisms as surrogate (codes: ICD9 =303;
ICD-10=F10.1-F10.9) with 181,862 individuals affected.
Confidence intervals (95%CI) were calculated assuming
a Poisson distribution.
Person-years of follow-up were calculated from date
of discharge with the first main diagnosis of AID until
death, emigration, or closing date, December 31, 2008.
The Cox regression analyses were used to estimate HRs,
which could be interpreted as mortality rate ratio.
Adjustments were done as above. The analyses were
for cause-specific deaths and deaths from other causes
were censored. The proportional hazard assumption for
the covariates was tested by Schoenfeld residuals and by
plotting the log of the negative log of the survival func-
tion versus the log of time.
The study was approved by the regional ethical review
board at Lund.
Results
The numbers of AID patients are shown in Table 1 after
the name of the disease and the first column shows the
numbers of person-years at risk. Of the 33 AIDs ana-
lyzed, 21 had more than 3 cases of myelomas and these
are shown in the Tables. For myeloma after any AID,
including the ones not shown, the SIR was increased to
1.12, while the HR was 0.92 (not significant, Table 1).
SIRs were significantly increased after ankylosing spon-
dylitis (2.02) and systemic sclerosis (2.63). No SIR was
significantly decreased. Only the HR after rheumatic
fever (5.27) was significantly increased.
The data were analyzed according to the age at
myeloma diagnosis (Table 2). Note that the number of
patients followed for myeloma was the same as in Table 2.
The overall risk of myeloma was increased only for those
diagnosed before age 60 years (SIR 1.45); the signifi-
cant SIRs were noted for ankylosing spondylitis (3.31),
chronic rheumatic heart disease (2.79) and systemic
lupus erythematosus (5.19). The HRs in young patients
were increased after Graves/hyperthyroidism (2.48),
rheumatic fever (21.17, but only one death) and sys-
temic sclerosis (5.51). In myeloma patients diagnosed at
age 60+ years, only the risk for systemic sclerosis was
increased (2.59). HRs were increased after polymyositis/
dermatomyositis (5.40) and rheumatic fever (4.60).
In Table 3 the data were analyzed in two periods,
1964 to 1990 and 1991 to 2008; the patient numbers are
shown in the parentheses. The overall SIR was only
Table 1 SIRs and HRs for myeloma after a specified AI disease
Autoimmune disease (case numbers) Pyrs O SIR 95%CI Deaths HR 95%CI
Ankylosing spondylitis (6646) 112824 16 2.02 1.15-3.28 4 0.60 0.22-1.59
Behcet disease (3874) 63182 6 1.48 0.53-3.23 3 0.64 0.21-1.98
Chronic rheumatic heart disease (21027) 166242 23 0.92 0.58-1.39 9 0.93 0.48-1.79
Crohn disease (25677) 392264 15 0.82 0.46-1.36 9 1.20 0.62-2.31
Graves/hyperthyroidism (42020) 541104 52 1.03 0.77-1.35 29 0.88 0.61-1.27
Hashimoto/hypothyroidism (13160) 120705 15 1.14 0.64-1.89 4 0.40 0.15-1.06
Immune thrombocytopenic purpura (4324) 44220 4 2.13 0.55-5.51 2 0.57 0.14-2.30
Multiple sclerosis (14616) 185014 13 0.99 0.53-1.70 8 1.25 0.62-2.49
Myasthenia gravis (3044) 32648 4 1.35 0.35-3.49 3 1.85 0.60-5.74
Pernicious anemia (11590) 67096 13 1.01 0.54-1.74 12 1.15 0.65-2.03
Polymyalgia rheumatica (27534) 253046 43 1.20 0.87-1.62 27 1.05 0.72-1.53
Polymyositis/dermatomyositis (2465) 24041 4 1.80 0.47-4.65 3 1.41 0.45-4.38
Psoriasis (19777) 275971 23 0.98 0.62-1.47 11 0.75 0.41-1.35
Rheumatic fever (4306) 77388 8 1.34 0.57-2.65 6 5.27 2.37-11.75
Rheumatoid arthritis (72309) 731954 81 0.88 0.70-1.09 45 0.93 0.69-1.24
Sarcoidosis (11571) 177765 19 1.30 0.78-2.03 11 1.05 0.58-1.90
Sjögren syndrome (1957) 16700 4 2.10 0.55-5.42 1 0.30 0.04-2.13
Systemic lupus erythematosus (7624) 86627 11 1.71 0.85-3.07 5 1.10 0.46-2.63
Systemic sclerosis (7169) 89997 19 2.63 1.58-4.11 13 0.92 0.53-1.60
Ulcerative colitis (33493) 486704 38 1.36 0.96-1.87 21 0.96 0.62-1.47
Wegener granulomatosis (15833) 115746 26 1.17 0.76-1.72 6 0.77 0.47-1.26
All (402462) 4777665 457 1.12 1.02-1.23 251 0.92 0.81-1.04
Bold type indicates that the 95% CI does not include 1.00.
Abbreviations: Pyrs, person-years; O, observed; SIR, standardized incidence ratio; CI, confidence interval; HR, hazard ratio.
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to 1990 (1.31), systemic sclerosis showing the only
significant association (3.60). The overall HR was not
changed for this period, but increased HRs for myeloma
were noted after multiple sclerosis (4.02), rheumatic fever
(5.06) and systemic lupus erythematosus (15.48). In
period 1991–2008, the overall SIR was not increased and
myeloma was increased only after ankylosing spondylitis
(2.09). HRs for myeloma were increased in polymyositis/
dermatomyositis (6.44) and rheumatic fever (4.43)
patients.
Discussion
Myeloma remains a fatal disease even though the relative
survival in Sweden has increased from 19% in 1964 to
39% in 2003 [22]. The improvements have been ascribed
to more effective treatment modalities, which include
melphalan-prednisone covering the present study period
and interferon alpha since the late 1970s [19]. High-dose
melphalan therapy and autologous stem-cell trans-
plantation were introduced in Sweden in the late 1980
and thalidomide began to be used about a decade later[19]. Thus, in the latter part of our follow-up period
(1991–2008), many therapeutic innovations were in use,
and the overall myeloma risk and survival were iden-
tical in AID patients and the population not hospitalized
for AIDs. The risk of myeloma remained elevated for
ankylosing spondylitis patients and was still of borderline
significance for systemic sclerosis patients, although the
SIR had decreased compared to the earlier part of the
follow-up period (1964–1990). Risk of myeloma before
age 60 years was increased in chronic rheumatic heart
disease and systemic lupus patients.. Ankylosing spondyl-
itis and systemic sclerosis were associated with myeloma
in the earlier US study on male veterans [4]. In that
study, myeloma risk was associated with a few other
AIDs that were not associated with myeloma risk in our
study, probably partly for statistical reasons: there were
4,641 cases of myeloma in the US study compared with
457 in the present study. Another reason may be the
gender, as only males were included in the US study.
We have been unable to find previous publications
documenting adverse (or beneficial) effects of AID for
myeloma survival. The reasons for poorer survival in
Table 2 SIRs and HRs for myeloma after a specified AI disease by age at cancer diagnosis
Autoimmune disease Pyrs
0<Age<60 Age60
O SIR 95%CI Deaths HR 95%CI O SIR 95%CI Deaths HR 95%CI
Ankylosing spondylitis 112824 8 3.31 1.41-6.55 3 1.00 0.32-3.11 8 1.45 0.62-2.87 1 0.29 0.04-2.01
Behcet disease 63182 2 1.99 0.19-7.32 0 4 1.31 0.34-3.38 3 1.05 0.34-3.24
Chronic rheumatic heart disease 166242 6 2.79 1.00-6.11 4 1.25 0.47-3.33 17 0.75 0.43-1.20 5 0.82 0.34-1.96
Crohn disease 392264 5 0.89 0.28-2.09 3 1.47 0.47-4.57 10 0.79 0.38-1.46 6 1.12 0.50-2.50
Graves/hyperthyroidism 541104 7 0.98 0.39-2.04 5 2.48 1.03-5.98 45 1.04 0.76-1.39 24 0.80 0.53-1.19
Hashimoto/hypothyroidism 120705 1 0.85 0.00 -4.87 0 14 1.17 0.64-1.97 4 0.44 0.16-1.16
Immune thrombocytopenic purpura 44220 0 4 2.51 0.65-6.50 2 0.57 0.14-2.27
Multiple sclerosis 185014 3 0.86 0.16-2.56 0 10 1.04 0.49-1.92 8 1.84 0.92-3.68
Myasthenia gravis 32648 1 2.60 0.00-14.91 1 2.41 0.34-17.14 3 1.16 0.22-3.45 2 1.55 0.39-6.18
Pernicious anemia 67096 1 2.38 0.00-13.63 1 0.49 3.06-3.48 12 0.97 0.50-1.70 11 1.30 0.72-2.35
Polymyalgia rheumatica 253046 5 1.93 0.61-4.55 3 0.94 0.30-2.92 38 1.14 0.81-1.57 24 1.05 0.70-1.56
Polymyositis/dermatomyositis 24041 1 3.19 0.00-18.26 0 3 1.57 0.30-4.65 3 5.40 1.75-16.65
Psoriasis 27591 5 1.19 0.38-2.80 1 0.43 0.06-3.06 18 0.94- 0.55-1.48 10 0.80 0.43-1.49
Rheumatic fever 77388 1 0.76 0.00-4.35 1 21.17 2.96-151.59 7 1.50 0.60-3.11 5 4.60 1.91-11.06
Rheumatoid arthritis 731954 8 0.90 0.39-1.79 2 0.45 0.11-1.89 73 0.88 0.69-1.10 43 0.96 0.71-1.29
Sarcoidosis 177765 4 1.26 0.33-3.27 2 1.19 0.30-4.78 15 1.31 0.73-2.16 9 1.07 0.55-2.05
Sjögren syndrome 16700 1 4.58 0.00-26.27 0 3 1.78 0.33-5.26 1 0.34 0.05-2.38
Systemic lupus erythematosus 86627 6 5.19 1.87-11.36 3 1.42 0.46-4.41 5 0.95 0.30-2.23 2 0.86 0.22-3.45
Systemic sclerosis 89997 3 2.87 0.54-8.49 3 5.51 1.75-17.29 16 2.59 1.47-4.2 10 0.80 0.43-1.49
Ulcerative colitis 486704 11 1.50 0.75-2.70 6 0.85 0.38-1.89 27 1.31 0.86-1.90 15 1.05 0.63-1.74
Wegener granulomatosis 115746 2 3.91 0.37-14.36 2 1.91 0.48-7.68 24 1.11 0.71-1.65 14 0.71 0.42-1.20
All 4777665 84 1.45 1.16-1.80 40 0.96 0.70-1.32 373 1.07 0.96-1.18 211 0.92 0.80-1.06
Bold type indicates that the 95% CI does not include 1.00.





















Table 3 SIRs and HRs for myeloma after a specified AI disease by diagnostic period of cancer
Autoimmune disease
(case numbers in the two periods)
1964-1990 1991-2008
Pyrs O SIR 95%CI Deaths HR 95%CI Pyrs O SIR 95%CI Deaths HR 95%CI
Ankylosing spondylitis (4692/1954) 39322 3 1.73 0.33-5.12 1 3.60 0.50-25.72 73502 13 2.09 1.11-3.59 2 0.40 0.10-1.59
Behcet disease (3635/239) 28513 3 2.14 0.40-6.35 3 1.38 0.45-4.29 34669 3 1.12 0.21-3.33 0
Chronic rheumatic heart disease (17015/4012) 85701 13 1.16 0.62-1.99 6 1.55 0.70-3.46 80541 10 0.73 0.35-1.35 2 0.43 0.11-1.73
Crohn disease (12733/12944) 110614 3 1.01 0.19-3.00 1 1.19 0.17 -8.43 281650 12 0.78 0.40-1.37 6 1.22 0.55-2.71
Graves/hyperthyroidism (26633/15387) 203693 22 1.32 0.82-2.00 8 0.61 0.31-1.23 337411 30 0.89 0.60-1.27 15 1.17 0.71-1.95
Hashimoto/hypothyroidism (8375/4785) 43501 8 1.88 0.80-3.72 3 1.16 0.37-3.59 77204 7 0.79 0.31-1.64 0
Immune thrombocytopenic purpura (965/3359) 8640 1 4.44 0.00-25.4 1 0.53 0.07-3.73 355800 3 1.81 0.34-5.37 1 0.61 0.09-4.35
Multiple sclerosis (8782/5834) 67706 4 1.03 0.27-2.67 2 4.02 1.01-16.01 117308 9 0.97 0.44-1.86 5 1.14 0.47-2.73
Myasthenia gravis (1551/1493) 10430 2 2.91 0.27-10.7 0 22218 2 0.88 0.08-3.23 2 1.92 0.48-7.67
Pernicious anemia (9687/1903) 32746 5 0.83 0.26-1.96 3 0.72 0.23-2.22 34350 8 1.17 0.50-2.32 7 1.37 0.66-2.88
Polymyalgia rheumatica (13278/14256) 72444 10 1.59 0.76-2.94 5 1.35 -0.563.24 180602 33 1.12 0.77-1.57 18 0.92 0.581-1.46
Polymyositis/dermatomyositis (1295/1170) 8310 1 1.57 0.00-9.00 0 15731 3 1.89 0.36-5.59 3 6.44 2.08-20.0
Psoriasis (14068/5709) 112458 11 1.51 0.75-2.71 5 0.78 0.32-1.88 163513 12 0.74 0.38-1.30 2 0.31 0.08-1.24
Rheumatic fever (3888/418) 34274 4 2.05 0.53-5.30 2 5.06 1.26-20.28 43114 4 0.99 0.26-2.57 3 4.43 1.43-13.7
Rheumatoid arthritis (49139/23170) 304697 35 1.02 0.71-1.41 16 0.81 0.49-1.32 427257 46 0.80 0.58-06 25 1.19 0.80-1.77
Sarcoidosis (7856/3715) 69124 9 2.17 0.98-4.14 6 1.31 0.59-2.93 108641 10 0.95 0.45-1.76 3 0.75 0.24-2.32
Sjögren syndrome (716/1241) 3386 1 3.10 0.00-17.7 1 0.87 0.12-6.15 13314 3 1.89 0.36-5.60 0
Systemic lupus erythematosus (4717/2907) 31854 4 1.93 0.50-4.99 4 15.48 5.79-41.42 54773 7 1.60 0.64-3.32 1 0.25 0.04-1.80
Systemic sclerosis (5795/1374) 36494 10 3.60 1.71-6.64 7 0.91 0.43-1.93 53503 9 2.02 0.92-3.85 5 1.35 0.56-3.25
Ulcerative colitis (17071/16422) 136018 5 0.95 0.30-2.23 1 0.27 0.04-1.95 350686 33 1.45 1.00-2.04 19 1.46 0.93-2.29
Wegener granulomatosis (14233/1600) 61898 14 1.20 0.65-2.02 3 0.32 0.10-1.00 53848 12 1.14 0.59-2.00 10 1.22 0.66-2.28
All (253449/149013)1696388 1696388 171 1.31 1.12-1.52 78 0.88 0.70-1.10 3081277 286 1.04 0.92-1.16 137 0.99 0.99-1.17
Bold type indicates that the 95% CI does not include 1.00.
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tion or non-tolerance of therapy, both of which have
been described for various cancers [23-25]. In the
Swedish study comparing periodic effects on myeloma
survival, the most favorable trends were seen for the
young patients who also received the most aggressive
therapies and were candidates for bone marrow trans-
plantation [19]. The present data showed no overall in-
fluence of AID on survival and the null results remained
when myeloma diagnostic age groups or periods were
considered. However, among individual AIDs, poor sur-
vival was observed for rheumatic fever, irrespective of
diagnostic age or period. Interestingly, rheumatic fever
has previously been shown as a risk factor for myeloma
which, however, was not evident in the present study
[12]. Rheumatic fever is caused by streptococcal infection
usually in childhood. The resulting carditis may develop
to congestive heart diseases and this was the likely
co-morbidity affecting survival; most of the affected
rheumatoid fever patients were 60+ years in the present
study. Other AIDs that appeared to worsen survival in
myeloma were polymyositis/dermatomyositis (only age
60+ and period 1991 to 2008) and multiple sclerosis and
systemic lupus erythematosus (only period 1964 to
1990), all quite devastating AIDs and likely to act as
co-morbidities.
The present paper is a continuation in a series of stud-
ies on cancers following AIDs, including so far digestive
tract, lung cancers and skin cancers [6,26-28]. Although
there is no general pattern of certain AIDs leading to
increases of all or most cancers, systemic sclerosis, lead-
ing to the highest SIR of myeloma, causes also significant
increases in esophageal cancer, lung adenocarcinoma and
squamous cell carcinoma and skin squamous cell car-
cinoma. Changes in survival (HR) are not as common as
changes in SIR, even in cancers previously studied, at
least in part because case numbers are less. We have
not previously observed increases in HR of cancer after
rheumatic fever.
In conclusion, the present data showed an increase
in myeloma SIR after two AIDs (ankylosing spondylitis
and systemic sclerosis) and HR after rheumatic fever.
The overall myeloma risk after any AID was no longer
increased in the latter follow-up period of 1991 through
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